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iomedical research and practice is in the midst
of a profound transformation that is being driven by two
primary factors: the massive increase in the amount of
DNA sequence information; and the development of
technologies to apply the new information.The principal
aim of the Human Genome Project,namely the elucida-
tion of the approximately 3 billion base pairs (bps) of the
entire genome, has almost been achieved. In February
2001,the analysis of the first draft of the sequence was
published,
1 and this analysis provided the first great sur-
prise: the total number of protein-coding genes was
nearer to 35 000 than the previously estimated 100 000.
2
The finished sequence of five entire human chromosomes
(chromosomes 22,21,20,14,and Y) has been published,
3-7
and for the 50th anniversary of the publication of the
structure of DNA by Watson and Crick
8 in April 2003,the
finished DNA sequence of the entire genome was made
available to the public by the International Human
Genome Sequencing Consortium (IHGSC) on the inter-
net. Over the past few years, more than 30 organisms
have had their genomes completely sequenced, with
another 100 in progress
9,10 and an at least partial DNA
sequence has been obtained for thousands of mouse and
rat genes. Consequently, we find ourselves at a time at
which new types of experiments are possible,and obser-
vations,analyses,and discoveries are being made on an
unprecedented scale.It can be expected that genetic con-
siderations will become important in all aspects of dis-
ease,be they diagnosis,treatment,or prevention.
Unfortunately,the billions of bases of DNA sequence do
not tell us what all the genes do,how cells work,how we
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The effect of variation in genes coding for drug targets
and for the enzymes involved in drug metabolism has
highlighted the genetic component of drug response.
Drug response can be likened to a complex, multifacto-
rial genetic trait, and the study of its genetic variation,
termed pharmacogenetics, is analogous to the study of
complex genetic disease in terms of the questions posed
and the analytical possibilities. Just as DNA variants are
associated with specific disease predispositions, so will
they be associated with individual response to certain
drugs. The testing for drug response is following the
same route as the genetic testing for inherited disorders,
and has reached the stage where genome-wide analy-
sis, as opposed to the analysis of single genes, is a real-
ity. In this article, we will discuss some of the technical
advances that facilitate such analyses, leading to faster
and more extensive diagnostic capabilities.
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paper—how a particular subject will respond to a par-
ticular drug.The latter forms the stuff of the future,and
this rather broad field has been given the name “func-
tional genomics.”This review attempts to describe the
application of genomics to the problem of drug response,
and examine future possibilities for effective genetic test-
ing for drug response.The overall incidence of adverse
drug reactions (ADRs),at least in American hospitals,is
about 6.7%;fatal ADRs occur with an incidence of about
0.3%.
11These unanticipated reactions to medications are
largely,if not entirely,genetically determined.By defin-
ition,pharmacogenetics is the study of variability in drug
responses attributed to genetic factors in different pop-
ulations.
12 In its narrowest sense,pharmacogenetics can
be restricted to those genetic variations that alter the
ability of the body to absorb,transport,metabolize,or
excrete drugs or their metabolites.In broader and more
useful terms,pharmacogenetics encompasses any genet-
ically determined variation in response to drugs. This
type of variation includes,for instance,the effect of bar-
biturates in precipitating clinical disease in persons with
acute intermittent porphyria, an autosomal dominant
inherited disease associated with intermittent neurolog-
ical dysfunction, as well as the effect of alcohol use by
pregnant women on the incidence of fetal alcohol syn-
drome. Pharmacogenomics is the determination and
analysis of the genome (DNA) and its products (RNA
and proteins) as they relate to drug response.
12
Medicine would surely be revolutionized if one could pre-
dict a response before medication and provide a statisti-
cal probability of a good or bad response.Current drug
therapy is very much “one size fits all,”and the costs of the
administration of ineffective drugs and the compensation
for serious ADRs of unsuitable medication are immense,
not to mention the high number of deaths caused by
severe ADRs.The long-term goal of pharmacogenetics is
to one day offer personalized medicine,so that clinicians
can choose the best treatment for each individual patient.
Genetic variation and current testing 
for monogenic disorders
It has been well known for many years that DNA
sequence is highly variable,even within populations.DNA
variation can be in the form of single nucleotide substitu-
tions,the deletion or insertion of one or more nucleotides,
or the variable repetition of a number of nucleotides
(small tandem repeats [STRs] or longer variable number
of tandem repeats [VNTRs]).Neutral DNA changes or
“variants” (with respect to selective pressures) are
referred to as polymorphisms when their rarest allele is
present in more than 1% of chromosomes in a particular
population.Mutations,on the other hand,are rare differ-
ences that occur in less than 1% of the population (usu-
ally much less than 1%) and have typically been discov-
ered in the coding sequences of genes causing rare
inherited diseases. How neutral the so-called polymor-
phisms really are is merely assumed on the basis of their
lack of direct association with a particular phenotype.
However,it is feasible to assume that a particular variant
may produce a particular phenotype when in combination
with particular alleles of other such variants.
The ability to screen particular genes for mutations has
developed into an important diagnostic tool,and genetic
testing for disorders that are inherited in a mendelian fash-
ion (primarily single-gene disorders,so-called monogenic)
is already well established in medical practice.This is rela-
tively easily performed for monogenic disorders when the
causative gene is known,eg,cystic fibrosis,hemophilia,var-
ious forms of muscular dystrophy,mental retardation,and
late-onset neurological disorders.Testing for mutations in
specific disease genes can help diagnose the disease,
determine the carrier status of an individual,and predict
the occurrence of the disease.Thus,predictive or presymp-
tomatic testing for late-onset neurological disorders,such
as Huntington’s disease or cerebellar ataxia in younger rel-
atives of patients,is well established.Moreover,kits for the
diagnosis of several human disorders (via mutation detec-
tion) including cystic fibrosis,β-thalassemia,and Tay-Sachs
disease,among others,are commercially available.
The problem of genetic heterogeneity
Even from these single-gene disorders,we have indica-
tions that the situation is not that simple.Geneticists are
familiar with terms such as “epigenetics,”ie,genetic phe-
nomena that cannot be explained by traditional genetics.
Basic research
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ADR adverse drug reaction
AD Alzheimer’s disease
bp base pair
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LD linkage disequilibrium
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One example of this is disease transmission and severity
being affected by the sex of the transmitting parent and
“modifying factors”(probably other genes that affect dis-
ease severity); this is the case for cystic fibrosis
13 and
hemochromatosis.
14We increasingly observe that,even if
the gene causing the disorder is known, the pheno-
type–genotype relationship is not clear.
This genetic heterogeneity poses a real problem for diag-
nostic testing.The connection between a patient’s symp-
toms,diagnosis,and the underlying mechanism of disease
is often obscure.For example,patients with mutations in
different genes may present as clinically identical,while
patients with the same mutation may present clinically
disparate.
Alzheimer’s disease (AD) is an oft-quoted example of a
disorder with different forms of inheritance and illus-
trates the problem that genetic heterogeneity creates for
diagnostic testing.Early-onset AD is strongly familial,
whereas late-onset AD is considered a complex disease
with strong environmental influences.Mutations in the
APP,presenilin 1 (PS1),and presenilin 2 (PS2) genes can
cause clinically indistinguishable forms of early AD.
15-17
On the other hand,different mutations in the same gene,
eg,APP,can lead to two distinct diseases,early-onset AD
and recurrent intracerebral hemorrhage.
18
The more disease genes that are discovered, the more
apparent this phenomenon becomes.Another example
is mutations in the androgen receptor gene (AR) in
which the expansion of the trinucleotide triplet repeat
CAG in the first exon of the gene leads to adult-onset
motor neuron disease
19 (spinal and bulbar muscular atro-
phy [SBMA] or Kennedy disease), whereas different
types of mutations in the other exons of the same gene
lead to androgen insensitivity
20;these are two completely
different pathologies.
Thus, it is not hard to imagine that the situation is even
more complex for polygenic disorders,which are caused
by many different genes and have an environmental com-
ponent.For most common diseases,such as schizophrenia,
severe depression,diabetes,asthma,and psoriasis,which
affect a much more significant percentage of the popula-
tion than the single-gene disorders mentioned above,the
situation is apparently far more complicated, hence the
name “complex disorders.”Some examples of single-gene
and polygenic disorders are provided in Table I.
21-32
Current testing for drug response: 
metabolizing enzymes
Until very recently,the genetic testing for drug response
could be likened to the testing for the monogenic inher-
ited disorders described above.Differences between the
rates of drug metabolism among people,associated with
particular polymorphic forms of enzymes involved in
drug catabolism,have been known for decades.Garrod
33
first suggested that genetically controlled enzymes
responsible for the detoxification of foreign compounds
may be lacking in some individuals.Kalow
34 succeeded in
associating enzyme abnormality (serum cholinesterase)
with drug sensitivity (succinylcholine).During the 1960s
Table I. Examples of single-gene and polygenic disorders and their mutations or susceptibility loci.
Monogenic disorders  Gene mutations
(mendelian inheritance) 
Single gene, single mutation, eg, Huntington’s disease Expansion of CAG repeat in IT15 gene
21
Single gene, many known mutations, eg, cystic fibrosis >1291 mutations in CFTR gene
22
More than one gene, each with its own mutations  Mutations in SHH, TGIF, SIX3, HNF3 , and ZIC2 genes
23
(extensive genetic heterogeneity), eg, holoprosencephaly 
(midline defect in developing forebrain and face)
Polygenic disorders  Susceptibility loci
(nonmendelian, complex inheritance) (more subtle effect of change in gene; 
many changes together cause the disease)
Late-onset Alzheimer’s disease Chromosomal regions 19q13 (APOE gene)
24 and 12q
25
Type 2 diabetes mellitus Chromosomal regions 12q
26 and 2q
27
Asthma Chromosomal region 12q
28
Migraine Chromosomal region 19p13
29
Psoriasis  Chromosomal regions 3q21,
30 6p,
31 and 17q
32and 1970s, Harris
35 matched structural gene mutations
with physiological and pathological data in hemoglo-
binopathies and enzymopathies.Since then,a large num-
ber of polymorphisms in metabolizing enzymes have
been described, which are known to contribute to
interindividual differences in the pharmacokinetics of
many drugs. The origin of polymorphisms for drug
response,and the mechanisms by which they are main-
tained,pose an interesting problem.They obviously have
not developed in response to drugs,because they ante-
date the drugs concerned. It has been suggested that
these polymorphisms arose as the result of different
dietary selective pressures in different populations.
36
External compounds have to follow a succession of oxi-
dations reactions (phase I) and conjugations (phase II)
by metabolizing and transporting enzymes to be assimi-
lated and then secreted by an organism.Mutations in the
genes coding for metabolizing enzymes can affect the
incorporation or elimination of foreign compounds,
resulting in their toxic accumulation or rapid elimination
from the organism. Polymorphic DNA variants within
genes have been found to have the same effect.Although
these polymorphisms may not directly influence the
drug’s therapeutic value, the metabolizing rate will be
affected and the therapeutic dose will have to be adjusted
to the patient’s phenotype to achieve maximum efficacy
and minimal ADRs.
Interindividual response variation could not be explained
on the basis of metabolizing polymorphisms only,and the
research field was extended to include the drugs’ site of
action.Mutations altering the neurotransmitter receptor
and transporter systems targeted by antipsychotics and
antidepressants (for example,mutations in dopamine and
serotonin receptor and transporter genes) may also play
an important role in treatment outcome.This topic has
been extensively researched and reviewed in the psychi-
atric genetics literature (see,for example,references 37
and 38) and therefore will not be described in detail here.
The analysis of the cytochrome P450 (CYP) genes will be
summarized, as they have retained their relevance for
drug response testing using current methodologies.
Drug treatment of psychiatric disorders is troubled by
severe adverse effects,low compliance,and a lack of effi-
cacy in about 30% of patients. Consequently, much
research has been performed on metabolizing enzymes,
such as the CYP enzymes and the effect of their variation
on the efficacy and tolerability of commonly used
antipsychotic and antidepressant drugs.Twelve families
of CYP enzymes have been described, of which four
(CYP1 to CYP4) are directly involved in drug metabo-
lism.
39They constitute the best-studied family of xenobi-
otic-metabolizing enzymes. Mutations in the genes
CYP2D6, CYP2C9, and CYP2C19 have already been
shown to be the cause of altered drug pharmacokinet-
ics.
40-42 Possibly the most-studied drug-metabolizing
enzyme is CYP2D6, which may be involved in the
metabolism of up to 25% of commonly used drugs.
43
Mutations in the CYP2D6 gene have been found to be
responsible for phenotypic variation in the metabolism
of debrisoquine,and individuals can be classified as poor
metabolizers (PMs),intermediate metabolizers (IMs),
extensive metabolizers (EMs),or ultrarapid metaboliz-
ers (UMs).Ninety-five percent of the PMs are generally
homozygous for two of the mutations or the deletion of
the entire CYP2D6 gene. Polymerase chain reaction
(PCR) methods are available for the rapid detection of
these mutations as well as mutations in other drug-
metabolizing enzyme genes,such as CYP2C9,CYP2C19,
and cytosolic N-acetyltransferase 2 gene (NAT2), in
order to facilitate the prediction of an individual’s metab-
olizing rates.
Due to the high frequency of mutations in metabolizing
enzymes in the general population, they will probably
remain important in the success of therapeutic treatment.
It has been proposed that variation in metabolizing
enzymes,and variation in drug targets or receptors,com-
bine to fully explain the heterogeneity in response to psy-
chiatric treatment.DNA chips (see below) for the detec-
tion of CYP2D6 and CYP2C19 mutations have already
been developed for the identification of PMs
44,45 and
these will be combined with the pharmacogenetic single
nucleotide polymorphism (SNP) profiles described in the
next section to predict,with a high degree of accuracy,
individuals who are likely to have an ADR to a medica-
tion,even without specific knowledge of the metabolism
of the drug or of the specific alleles that modulate
responses to it.
SNPs and the testing for 
common complex disorders
If a region of the human genome is sequenced from two
randomly chosen individuals,99% of the examined DNA
will be identical.Of the 0.1% that differs,more than 80%
will be SNPs.
46 SNPs represent a single bp variation (for
example,a C to T transition) between individuals in the
Basic research
30population, where each version of the variant (in the
above example,C or T) is observed in the general popu-
lation at a frequency of more than 1%.
47,48 This type of
variation,has been known and applied to genetic analy-
sis for the last two decades,
49 but was originally detected
using the rather laborious method of Southern blotting.
50
The recent technological development of quick, high-
throughput methods for genotyping has projected SNPs
into the limelight over the last few years.
51Added to this
is the fact that SNPs are abundant and occur throughout
the human genome,in regulatory,coding,and noncoding
regions, with an average frequency of approximately
1 per 1000 bp.
48When it falls within coding regions,the
variant may actually result in an amino acid change,
which in turn may be of medical significance.
A major interest among research groups concentrating
on SNPs is the identification of the genetic variation that
underlies common, complex traits. It is no coincidence
that these are the ailments for which the pharmaceuti-
cal companies are most interested in developing new
drugs and being able to test for the efficacy of their
drugs. The SNP Consortium (TSC), which comprises
pharmaceutical and bioinformational companies, five
academic centers,and a charitable trust,is currently pro-
ducing an ordered high-density SNP map of the human
genome. Mapped SNPs are regularly being placed on
public domain websites.TSC’s  mission was to develop
up to 300 000 SNPs distributed evenly throughout the
human genome and,at the beginning of 2001,they pub-
lished a map containing 1.4 million SNPs.
53 More
recently,a high-resolution human SNP linkage map with
a resolution of 3.9 centimorgans, and an SNP screening
set was published.
54
Since SNPs constitute the bulk of human genetic varia-
tion,they can be used to track the inheritance of genes in
traditional family-based linkage studies.On a larger scale,
though,they can be used to track associations to disease,
without necessarily finding each functionally important
SNP,due to a phenomenon called linkage disequilibrium
(LD).LD occurs when combinations of alleles at differ-
ent loci occur more frequently together than would be
expected from random association.LD fades with time
(in successive generations),at a rate depending on the
amount of recombination that occurs during meiosis
between the loci.The closer two SNP loci are together on
a chromosome,the more likely they are to be inherited
together than those that are further apart. Therefore,
SNPs that are close to or within a particular gene are
likely to be inherited together with the gene when they
are in LD,and the variation of particular SNPs can act as
markers for particular forms of the gene.
Combinations of alleles are referred to as haplotypes,and
the study of haplotypes has been instrumental in analyz-
ing the link between genetic variation and disease pre-
disposition.A haplotype block can be defined by a set of
SNPs on a chromosome and ranges from 3 to 150 kb.The
National Human Genome Research Institute (Bethesda,
Md) is sponsoring research to construct a human haplo-
type map to help find those chromosome regions that are
associated with diseases,and the success of this approach
has been verified experimentally by reidentifying the
APOE4 allele as a susceptibility factor for earlier age-of-
onset AD, using a high-density SNP mapping analysis
across the 4 million base region that contained the
APOE gene.
55,56 Similarly,a susceptibility locus for schiz-
ophrenia on chromosomal region 6p22,which was first
identified by linkage analysis in families, was recently
confirmed by SNP haplotype analysis.
57Although results
have been slow in coming, in practice, LD association
mapping has identified susceptibility loci for both pso-
riasis and migraine.
29,58The hypothesis is that,in a similar
way,haplotypes will be associated with particular drug
responses.The concept of using SNPs to develop an SNP
profile is illustrated in Figure 1.
Genetic testing in the future: new technology
There is a general tendency in human genetics to move
away from studies of single genes to genome-wide
approaches.The genetic testing for inherited disorders is
following the same trend and,similarly,the emphasis in
testing for drug response will move from the analysis of
single genes affecting drug metabolism,to the large-scale
analysis of genetic variation in relation to drug response.
Instead of investigating polymorphisms close to candi-
date genes, thousands of variants (SNPs) across the
genome will be typed and organized into an individual
“fingerprint,”also referred to as an SNP print
12 or,for the
sake of this review, an SNP pharmacogenetic profile.
Multiple, closely ordered polymorphisms, which are
inherited together over many generations and are there-
fore in LD, will distinguish particular regions of the
genome.The objective will be to rapidly identify a genetic
profile that characterizes patients who are more likely to
suffer an ADR,compared with other patients who are
likely to respond to the drug safely.
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31There are various factors that can confound such analyses,
one very important consideration being ethnic differences
between patients.The allele frequencies of DNA poly-
morphisms such as SNPs are highly variable between pop-
ulations,so that population admixture may mask,blur,or
alter the LD patterns.
59 Secondly,ethnic variation in drug
response is well known:in World War II it was discovered
that African-American soldiers who were treated with the
antimalarial drug primaquine developed hemolytic ane-
mia crises at high altitudes, due to glucose-6-phosphate
dehydrogenase deficiency.
36 Hence,different SNP profiles
relating to drug response can be expected in different pop-
ulations. This concept is not new to genetic testing, for
example,mutation analysis for cystic fibrosis is already tai-
lored to patients with different ethnic backgrounds.
60
Essential to this progress is a scaling up of the applied
technology,and this is happening rapidly.The diagnostic
methods that are currently available in small molecular
genetic laboratories will be scaled up to test hundreds of
individuals simultaneously for hundreds of mutations or
DNA variants.Methods for the detection of SNPs on a
large scale have already been developed by several com-
panies
44,46 and are high on the agenda of most companies
involved in molecular biological research and develop-
ment.The industrial aim is to develop high-throughput,
accurate,sensitive,and cost-effective genetic diagnoses,
which in turn could lead to accurate,sensitive,and cost-
effective medication.
DNA arrays and chip technology
Most of the hope is placed on DNA arrays and chip tech-
nology,which have been developed over the last 5 years.
High-density DNA arrays allow complex mixtures of
RNA and DNA to be interrogated in a parallel and
quantitative fashion. While the making of arrays with
more than several hundred elements was until recently a
significant technical achievement,arrays with more than
250 000 different oligonucleotide probes or 10 000 dif-
ferent cDNAs (transcribed DNAs) per square centime-
Basic research
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Figure 1. Single nucleotide polymorphisms (SNPs): from a single SNP to an SNP profile. 
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ter can now be produced in significant numbers.
61,62 DNA
chips are simply glass surfaces bearing arrays of DNA
fragments at discrete addresses,at which the fragments
are available for hybridization.There are many variations
on the chip theme,but the general approach is as follows:
•To immobilize multiple DNA samples on a solid sup-
port,which are then interrogated (hybridized) with a
pool of oligonucleotide probes (a selected single-
stranded string of nucleotides) that are specific for par-
ticular mutations or DNA variants (allele-specific
oligonucleotides,ASOs).
•To immobilize oligonucleotides on a solid support,which
are then interrogated by individual DNA samples.
Either way, the sequence of the oligonucleotides that
hybridize to the DNA samples is determined,thus reveal-
ing the nature of the mutation or variant present in the
DNA sample.DNA chips are commonly used either to
monitor the expression of arrayed genes in mRNA sam-
ples from living cells or tissues, or to detect DNA
sequence polymorphisms or mutations in genomic DNA.
DNA chip technologies are distinguished by the sizes of
the arrayed DNA fragments,the methods of arraying,the
chemistries and linkers for attaching DNA to the chip,
and the hybridization and detection methods.The pro-
duction of a DNA chip for the analysis of DNA variants
or SNPs is shown in Figure 2.
One of the most prevalent uses of DNA arrays is to mea-
sure levels of gene expression (messenger RNA abun-
dance) for tens of thousands of genes simultaneously.Such
cDNA arrays consist of either thousands of inserts of
cDNA clones (transcribed DNA) by robotic deposition
onto a glass surface,representing up to 10 000 genes on an
area of 3.6 cm,or cDNA representing up to 30 000 human
genes,that are synthesized on a chip.These arrays allow the
comparison of fluorescently labeled cDNA populations
from control and experimental tissues (eg,disease- or drug-
treated tissue) in two colors.By scanning each color sep-
arately,differential gene expression can be assessed in an
internally controlled manner.This method of gene expres-
sion analysis is a convenient way to compare the efficacy
and side effects of drug candidates:cultured cells or ani-
mals are treated with several drug candidates that share
a common mechanism.A comparison of gene expression
changes often reveals changes that are mechanism-related
and are shared by such compounds,as well as changes that
are peculiar to one compound and suggest that the com-
pound has side effects.Such analyses can help clarify the
therapeutic mechanism of action of drugs.
Oligonucleotide arrays, upon which sets of oligonu-
cleotides represent different alleles of an SNP,are used
for the analysis of DNA variation.In this way,thousands
of SNPs can be read out automatically and rapidly.
63,64 By
applying whole-genome SNP LD mapping to patients
during phase 2 clinical trials of a drug,it may be possible
to select multiple small regions from the whole-genome
SNP map where SNPs are in LD and associated with effi-
cacy and common adverse event phenotypes.Selecting
only these small regions of SNP LD into abbreviated
SNP LD profiles will enable more rapid and inexpensive
screening of patients who are likely to experience effi-
cacy or ADRs in response to that drug.
65Thus,whereas
the phase 2 SNP scan might genotype up to 200 000 SNPs
for each patient,
66 the critical data used for identifying
markers for efficacy for subsequent phase 3 clinical trials
may use only several hundred SNPs from multiple small
regions in LD associated with efficacy or ADRs.
The cost of chips as a platform for drug response profil-
ing is likely to be reduced when analyses of hundreds of
thousands of patients are performed once the medicine
is marketed. In fact, each chip could contain a panel of
abbreviated SNP LD profiles for several drugs with the
same clinical indications, so that the most appropriate
medicine with that indication for that patient can be
determined from a single blood sample.Competition in
the biotechnology sector to develop industrial genotyp-
ing capacity has reduced the retail price of genotyping
some SNPs from US$1 to US$0.10 per SNP within 1
year,
12 and the prediction is a continued decrease in price
to less than US$0.01.There are ongoing technological
developments, eg, the extraction of DNA from a few
cells, from a buccal swab, and for the amplification of
human DNA and RNA, in order to produce sufficient
quantities from minute samples (eg, GenomiPhi
®,
Amersham).This will circumvent the need for a blood
sample and make individual sampling even easier. One
can predict that, in the future, metabolic screens of
genetic variants will be standardized so that automated
read-outs of each person’s predicted response to each
medicine can be generated.One possible scenario is the
rapid testing of a salvia sample within minutes in the
doctor’s office or the pharmacy, before prescribing or
delivering drugs.These DNA-based screens will not pro-
vide disease-specific diagnosis,but useful information to
aid in individual dosing of medications or avoidance of
ADRs. The information gained will produce a drug-
response genotype profile and finally more personalizedBasic research
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Figure 2. The development of an oligonucleotide array–based chip for single nucleotide polymorphism (SNP) analysis. P, polymorphism.
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Tmedicine, to ensure that the majority of people obtain
the drug with the highest efficacy and lowest adverse
effects.
Ethical considerations
One of the biggest challenges of the advances described
in this review will be to design tests to provide only infor-
mation relevant to the testing of response to a particular
drug,without additional prognostic value.It will be essen-
tial to exclude polymorphisms known to be associated
with specific diseases;however,this cannot exclude the
possibility that the diagnostic value of some of the poly-
morphisms used will only be exposed at a later stage.
Data management, protection, and privacy will be of
paramount importance,so that data are only used for the
purpose at hand.These problems already exist for the
testing of inherited disorders,and legal and ethical guide-
lines are continually being drawn up and revised to
accompany new developments.It will be vital to pass on,
adjust, and apply the experience from the testing for
genetic disorders to the practice of testing for drug
response.
Conclusions
Technical advances now allow faster and more reliable
diagnostic capabilities and in the future will make more
extensive screening programs a feasible option in both
practical and economic terms.Despite the rapid pace of
change in medical science,it seems certain that the iden-
tification of DNA alterations will remain a central part
of medicine in the future.Diagnostics and pharmacoge-
nomics are destined to a communal future.The transition
from the study of single genes or variants to multiples
thereof has been relatively slow;however,it is likely that
the benefits of the efforts of the last few years will soon
be reaped.
With the advancement of high throughput of genetic data
and the realization of the potential of pharmacogenomics
by the pharmaceutical companies, an explosion of data
leading to the individualization of treatment can be
expected.However,the day when each of us will have our
genotypes determined on a microchip in the doctor’s con-
sulting room before a drug is prescribed is far off.These
technologies are still in their infancy,with plenty of room
for further development,technical improvements,wide-
spread acceptance, and accessibility before they can be
routinely applied.The pattern of development and use of
arrays and other parallel genomic methodologies will
probably be similar to that seen for computers and other
high-technology electronic devices,which started out as
the exotic and expensive tools in the hands of a few devel-
opers and then quickly became easier to use,less expen-
sive,and more accessible.Probably most of the work lies
in developing computer models and software to extract
relevance from the mass of data produced from the test-
ing. It will be necessary to extract and identify complex
patterns embedded in the data via data mining.
All these advances will lead to the rapid development of
new diagnostic methods and therapeutic products using
genomic information and,hopefully,to the improvement
of patient care.Although pharmacogenetics is aimed at
improving patient care rather than acquiring knowledge
about disease genes,the latter may well be a spin-off of
the former. The initial impetus for pharmacogenetics
came from the search for disease genes and the estab-
lishment of molecular genetic diagnosis;however,in the
future the opposite can be expected.The subdivision of
the population into responders and nonresponders to a
particular drug may provide an invaluable starting point
for the association of genetic variation with particular
phenotypes.When performed in an ethical way with a
laudable and healthy aim, pharmacogenetics and the
effective testing for drug response can provide hope for
a future of genetic testing in the best interests of patients
and their relatives. ❏
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El futuro de las pruebas genéticas para 
evaluar la respuesta a los medicamentos
El efecto de la variación en los genes que codifican
blancos de fármacos y las enzimas que participan en
el metabolismo de los medicamentos ha aclarado el
componente genético de la respuesta a los fárma-
cos. La respuesta a un medicamento puede asimi-
larse a un complejo rasgo genético, multifactorial, y
el estudio de su variación genética –llamada farma-
cogenética– es análogo al estudio de una enferme-
dad genética compleja en términos de las pregun-
tas que surgen y de las posibilidades de análisis. Así
como las variantes del DNA están asociadas con pre-
disposiciones a enfermedades específicas, así tam-
bién estarán asociadas con la respuesta individual a
ciertos fármacos. La evaluación de la respuesta a
medicamentos sigue el mismo camino que la eva-
luación genética de las enfermedades hereditarias,
y ha alcanzado un estado en que el análisis del
genoma completo, opuesto al análisis de genes úni-
cos, es una realidad. En este artículo se discuten
algunos de los avances técnicos que facilitan esos
análisis, lo que se traduce en capacidades diagnós-
ticas más rápidas y más completas.
L’avenir de l’analyse génétique pour la
réponse au médicament
L’effet de la variation des gènes codant les cibles
médicamenteuses et les enzymes impliquées dans
le métabolisme des médicaments a souligné la com-
posante génétique de la réponse au médicament.
Celle-ci peut être comparée à un caractère généti-
que complexe et multifactoriel, et l’étude de sa
variation génétique, appelée pharmacogénétique,
est analogue à l’étude d’une maladie génétique
complexe en termes de questions posées et de pos-
sibilités analytiques. Tout comme les variantes de
l’ADN sont associées à des prédispositions spécifi-
ques à une maladie, elles seront aussi associées à
une réponse individuelle à certains médicaments.
L’analyse de la réponse au médicament suit le
même chemin que l’analyse génétique pour les
maladies héréditaires et a atteint le stade auquel
l’analyse du génome dans sa globalité, par oppo-
sition à celle des gènes individuels, est une réalité.
Dans cet article, nous discuterons quelques-unes des
avancées techniques qui facilitent de telles analy-
ses, conduisant à des possibilités de diagnostic plus
rapides et plus approfondies.Genetic testing for drug response - Morris-Rosendahl and Fiebich  Dialogues in Clinical Neuroscience - Vol 6 . No.1 . 2004
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